Bolt Biotherapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Redwood Citycaliforniathe Company Focuses On Developing Innovative Immunotherapies For Cancer Treatment Using Its Proprietary Boltbodya C Immune Stimulating Antibody Conjugateisacplatformthis Platform Combines Tumor Targeting Antibodies With Immune Stimulating Payloads To Activate Myeloid Cellssuch As Macrophages And Dendritic Cellsto Promote A Robust Anti Cancer Immune Response Bolt S Pipeline Includes Several Promising Therapiesbdc 1001 Is In Clinical Development For Her2 Positive Cancerswhile Bdc 3042 Is A First In Class Agonist Antibody Currently In A Phase 1 Trial For Various Solid Tumorsbdc 4182 Targets Claudin 18 2 And Is Expected To Enter Clinical Trials In Q2 2025The Company Collaborates With Genmab A Sinnovent Biologicsand Toray Industries To Enhance Its Isac Platform And Expand Its Therapeutic Applicationsunder The Leadership Of Ceo Willie Quinnbolt Aims To Efficiently Develop Therapies That Address Significant Unmet Needs In Oncology
